Slides
Page 1
.. Q2’FY 2027
Page 2
NOTES: 1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary 2. Closing Exchange Rate for USD 1 at Rs 95.83 as on September 30, 2026, Rs 94.84 as on March 31, 2026 and Rs 88.79 as on September 30, 2025. Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. Disclaimer 2
Page 3
Mr. Shyam S Bhartia Chairman & Mr. Hari S Bhartia Co-Chairman “We are pleased to report sustained strong growth momentum in Q2, with revenue growing by 24% YoY, and EBITDA growing by 51% YoY, reflecting disciplined execution across our businesses. Our quarterly EBITDA has more than doubled in three years, reflecting the successful execution of our Pinnacle strategy and disciplined cost management. This momentum was also reflected in our strong H1 performance, with revenue increasing by 25% and EBITDA by 44%. We are delighted to have signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited, marking our entry into the EDMS space, which will help us in offering an integrated value proposition to our customers in Electronics/Semicon sectors. Markets Update: Amid continued geopolitical uncertainties, volumes remained stable, while firmer crude prices supported improved realizations . The quarter also witnessed higher input and utility costs, which partially offset the benefits of improved pricing. The Pharmaceutical sector continued to grow on the back of steady volumes driven by sustained demand for intermediates. The Agrochemicals segment continued to be under pressure with steady volumes and muted pricing, driven by China overcapacity In Personal Care, we are witnessing strong volume growth and increasing traction with new customers seeking outsourcing partnerships. The Nutrition segment maintained steady volumes, despite softening B3 pricing in the feed segment in last few weeks. In Semiconductors and Electronics, we are witnessing a strong growth in the new -molecule pipeline, with encouraging customer traction, particularly from Japan. Future Outlook: Our Pinnacle journey continues to progress well, reflected in strong revenue and EBITDA growth, and a robust opportunity pipe line. We remain confident of sustaining this momentum, with growth expected across all three business segments in FY2027, particularly in Acetyls, where we hope to get higher volumes supported by plant closures in Europe . The new Multi-Purpose Plant remains on track for commissioning by year-end, strengthening our CDMO and Fine Chemicals growth roadmap.” Chairmen’s message on Q2’FY27 financial results 3
Page 4
4 Table of Contents The picture can't be displayed. The picture can't be displayed. 01. Q2’FY27 Highlights 02. Business Segments Update The picture can't be displayed. 03. ZettaOneUpdate 05 12 19
Page 5
.. The picture can't be displayed. Q2’FY27 Highlights 5
Page 6
Our business has become more ‘customer-centric’ with a higher focus on offering solutions across 6 focused end-verticals Specialty Chemicals • Pyridine and Picolines • Fine Chemicals: P&P and Diketene Derivatives, Cosmetics • CDMO: Agro, Pharma and Semicon Nutrition • Animal Nutrition: B3, Choline, Premixes • Human Nutrition: B3, CC/CBT, Premixes Chemical Intermediates • Acetic Anhydride • Ethyl Acetate • Acetaldehyde • Bio Acetic Acid Pharma Agro Nutrition Industrial Personal Care Electronics/ Semicon Our 3 BUs offer solutions…. …across 6 focused verticals 6
Page 7
• Overall growth was led by stronger realizations and an improved product mix • Specialty Chemicals witnessed improved pricing, with Fine Chemicals and CDMO leading the pack • Nutrition business delivered healthy growth, supported by higher volumes, improved pricing and a favourable product mix • Chemical Intermediates witnessed improved pricing both YoY and QoQ, with volumes remaining steady Financial results overview: Q2’FY27 consolidated 7 Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 Q-o-Q Y-o-Y H1'FY26 H1'FY27 Y-o-Y Total Revenue 1,121 1,300 1,394 7% 24% 2,159 2,695 25% Total EBITDA 146 209 221 6% 51% 300 431 44% EBITDA Margin (%) 13% 16% 16% 14% 16% PAT after Exceptional Items 69 106 111 5% 61% 145 217 50% PAT Margin (%) 6% 8% 8% 7% 8% Basic and Diluted EPS (Rs.) 4.4 6.7 7.1 6% 61% 9.2 13.8 50%
Page 8
FY24 FY25 FY26 FY27 Revenue (Rs. Crs) 1075 1020 966 1074 1022 1045 1057 1051 1038 1121 1051 1179 1300 1394 125 126 104 101 119 135 148 155 153 146 136 172 209 221 11.6% 12.4% 10.8% 9.4% 11.6% 12.9% 14.0% 14.7% 14.8% 13.1% 12.9% 14.6% 16.1% 15.9% -20 30 80 130 180 230 Achieved highest ever revenue & highest EBITDA in the last 16 quarters 8
Page 9
• Pyridine business remained stable despite pricing softness • CDMO and Fine Chemicals gained momentum, aided by new launches and improved realizations • Strong volume growth in B3 & B4 • Rising contribution from high-value products such as cosmetic grade and premixes • Remidex ramp-up further supported volume growth • Ethyl Acetate volumes grew, while Acetic Anhydride volumes remained stable • Higher realizations across the portfolio drove EBITDA growth • Market share gains in Europe, with potential upside next year from plant shutdowns Specialty Chemicals Nutrition Chemical Intermediates EBITDA (INR Crs) Y.o.Y Growth 12% Q.o.Q Growth 1% EBITDA (INR Crs) Y.o.Y Growth 226% Q.o.Q Growth 13% EBITDA (INR Crs) Y.o.Y Growth 87% Q.o.Q Growth 9% 125 139 140 Q1 FY’27 Q2 FY’27Q2 FY’26 26% 26% 25% 20 57 64 4% 11% 11% 21 36 39 12% 15% 15% Q1 FY’27 Q2 FY’27Q2 FY’26 Q1 FY’27 Q2 FY’27Q2 FY’26 % EBITDA Margins – Before adjustment of Unallocated corporate expense/Income EBITDA trends: All three segments grew YoY 9
Page 10
Application wise Split HY’FY27 Balanced split of overall revenue across verticals, and consumers segment catching up fast Pharma 28% Nutrition 18% Industrial 27% Agro 20% Consumer 7% Business wise Split HY’FY27 Speciality Chemicals and Nutrition contribute ~60% of revenues Specialty Chemicals 40% Chemical Intermediates 40% Nutrition & Health Solutions 19% North America 9% Geography wise Split HY’FY27 ~46% business from Exports India 54% Europe 24% ROW 14% 10 Well-diversified and balanced portfolio; Pharma, Consumer and Nutrition are scaling up fast
Page 11
.. 11 Business Segments Overview
Page 12
Specialty Chemicals: Market, business & financial highlights Financial highlights • YoY and QoQ revenue growth led by higher Fine Chemicals and CDMO volumes • EBITDA grew YoY , driven by improved pricing across the value-added Fine Chemicals & CDMO portfolio P&P • Pyridine & Picolines volumes remained stable, while prices remained soft • Cost rationalization and Pyridine debottlenecking initiatives expected to support performance going forward Fine Chemicals • Pyridine/Diketene derivatives: Broad-based growth across products, supported by improved pricing, with the Diketene portfolio leading the growth • Cosmetics: Multiple products under development, with growing customer traction across sun care, skin care and hair care • Industrial: Continued volume traction with existing customers; discussions with several new customers CDMO • Agro: Strong volume growth in the Agro segment, supported by higher Agro Innovator CDMO volumes • Pharma: Strong pharma customer traction in the US and Europe, driving pipeline expansion, particularly with innovators • Semicon: Growing semicon inquiries and expanding application pipeline; upcoming R&D and clean-room facility in Greater Noida 1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 Q-o-Q Y-o-Y H1'FY26 H1'FY27 Y-o-Y Segment Revenue 485 533 560 5% 16% 963 1,093 14% % Share of Overall Revenue 43% 41% 40% 45% 41% EBITDA 125 139 140 1% 12% 255 280 10% % EBITDA Margin 26% 26% 25% 27% 26% % Contribution to EBITDA 2 75% 60% 58% 76% 59% 12
Page 13
Nutrition & Health Solutions: Market, business & financial highlights Financial Highlights • YoY and QoQ revenue growth was driven by strong Niacinamide volumes, supported by a favorable mix of value- added Food and Cosmetics products • Margins improved, supported by increased contribution from the cosmetics and food segment Human Nutrition • Vitamin B3: Strong YoY and QoQ growth in Niacinamide volumes, led by double-digit growth in Food and Cosmetics applications • CC/CBT: Improved volumes and pricing, underpinned by strong customer traction in the EU, US and India • Premixes: Remidex integration driving stronger engagement and sales traction with Tier-1 customers in India Animal Nutrition • Vitamin B3: Significant improvement in volumes during the quarter, with strong double-digit growth both YoY and QoQ, whereas pricing witnessed marginal pressure in last few weeks • Choline: Maintained domestic market share, sustained strong traction in the EU, and delivered sequential volume improvement • Premixes: Strong YoY and QoQ pricing improvement, supporting healthy margin performance 1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 Q-o-Q Y-o-Y H1'FY26 H1'FY27 Y-o-Y Segment Revenue 181 243 270 11% 50% 359 514 43% % Share of Overall Revenue 16% 19% 19% 17% 19% EBITDA 21 36 39 9% 87% 46 75 64% % EBITDA Margin 12% 15% 14% 13% 15% % Contribution to EBITDA 2 13% 15% 17% 14% 16% 13
Page 14
Chemical Intermediates: Market, business & financial highlights Financial Highlights • Revenue grew both YoY and QoQ, driven by steady volumes and improved realizations amid higher input costs from rising crude prices. • Strong YoY and QoQ EBITDA growth, driven by improved realizations across products Acetic Anhydride • Sequential volume growth supported by sustained pharma demand, market share gains in Europe, and stable domestic merchant market share • Strong double-digit price growth on YoY basis • Competitor closure in Europe expected to provide a significant boost to pricing and demand Ethyl Acetate • Ethyl Acetate recorded steady growth in sequential volumes • Significant pricing improvement on both YoY and QoQ basis, reflecting elevated input costs 1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 Q-o-Q Y-o-Y H1'FY26 H1'FY27 Y-o-Y Segment Revenue 455 524 563 8% 24% 836 1,088 30% % Share of Overall Revenue 41% 40% 40% 39% 40% EBITDA 20 57 64 13% 226% 36 121 232% % EBITDA Margin 4% 11% 11% 4% 11% % Contribution to EBITDA 2 12% 24% 26% 11% 25% 14
Page 15
The picture can't be displayed. ZettaOneUpdate
Page 16
ZettaOne Update: Building an integrated Electronics & Semiconductor platform ZettaOne Growth Trajectory Revenue (INR Cr) 51 79 99 FY24 FY25 FY26 FY27E Status Update • Execution of the deal is on track • Great customer traction, several customers bids in the pipeline • Joint GTM initiated with our Semicon/Electronics chemicals business - Customer reach out, Japan market visit, Semicon India Participation We have made an acquisition of a 40% strategic stake in Zettaone Technologies India Pvt. Ltd. for ₹189.2 Cr in cash through Jubilant Advanced Electronics Ltd (fully owned subsidiary of Jubilant Ingrevia) Acquisition of ZettaOne Technologies • Creating an integrated platform and product offering in the Electronics and Semiconductor space • Complementary capabilities to accelerate growth: o Jubilant brings scale, customer relationships, operational excellence, and CDMO capabilities o ZettaOne’ brings Design & Engineering depth, manufacturing expertise, and technical capabilities Integrated Value Proposition ~2x growth in last two years 60-70% growth expected in FY27 with mid-teen EBITDA 16
Page 17
.. Annexures
Page 18
Annexure I - Income Statement | Consolidated – Q2’FY27 Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others 1. All figures are in Rs Crore unless otherwise stated. 18 Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 QoQ YoY H1'FY26 H1'FY27 YoY Revenue from operations a) Sales/Income from operations 1110 1289 1381 7% 24% 2139 2670 25% b) Other operating income 11 12 13 13% 18% 20 25 26% Total revenue from operations 1121 1300 1394 7% 24% 2159 2695 25% Other income 11 10 9 -12% -16% 22 19 -13% Total income 1132 1310 1403 7% 24% 2181 2714 24% Expenses a) Cost of materials consumed 548 718 698 -3% 27% 997 1416 42% b) Purchases of stock-in-trade 31 64 23 -64% -25% 63 87 38% c) Changes in inventories of finished goods, stock- in-trade and work-in progress 22 -153 1 -101% -96% 60 -152 -354% d) Employee benefits expense 108 117 122 4% 14% 216 239 11% e) Finance costs 12 17 23 29% 85% 25 40 61% f) Depreciation and amortisation expense 41 51 51 0% 24% 82 102 24% g) Other expenses: - Power and fuel expense 107 138 123 -11% 15% 207 261 27% - Others 171 217 215 -1% 26% 339 432 27% Total expenses 1039 1170 1255 7% 21% 1988 2425 22% Profit before share of loss of an associate (3-4) 93 141 148 5% 59% 193 289 50% Share of loss of an associate -0.08 -0.03 -0.06 -0.06 Exceptional Items - Profit before tax 93 141 148 5% 59% 193 289 50% Tax expense - Current tax 15 43 23 -46% 51% 39 66 72% - Deferred tax charge 8 -8 13 -270% 67% 10 6 -42% Net profit for the period/year 69 106 111 5% 61% 145 217 50% Earnings per share of ₹ 1 each Basic (₹) 4.4 6.7 7.1 9.2 13.8 Diluted (₹) 4.4 6.7 7.1 9.2 13.7
Page 19
Annexure II: Income Statement Segmental – Q2’FY27 1. All figures are in Rs Crore unless otherwise stated. 19 Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 QoQ (%) YoY (%) H1'FY26 H1'FY27 YoY (%) Revenue Speciality Chemicals 485 533 560 5% 16% 963 1,093 14% Nutrition & Health Solutions 181 243 270 11% 50% 359 514 43% Chemical Intermediates 455 524 563 8% 24% 836 1,088 30% Total Revenue from Operations 1,121 1,300 1,394 7% 24% 2,159 2,694 25% Reported EBITDA 146 209 221 6% 51% 300 431 44% Speciality Chemicals 125 139 140 1% 12% 255 280 10% Nutrition & Health Solutions 21 36 39 9% 87% 46 75 64% Chemical Intermediates 20 57 64 13% 226% 36 121 232% Unallocated Corporate & One-Off (Expenses)/Income (20) (23) (22) - - (38) (45) - PAT 69 106 111 5% 61% 145 217 50% EPS 4.4 6.7 7.1 6% 61% 9.2 13.8 50% Reported EBITDA Margins 13% 16% 16% 14% 16% Speciality Chemicals 26% 26% 25% 27% 26% Nutrition & Health Solutions 12% 15% 14% 13% 15% Chemical Intermediates 4% 11% 11% 4% 11% Net Margin 6% 8% 8% 7% 8%
Page 20
Annexure III - Conference Call Details Date : October 27th, 2026 Time : 05:00 pm IST You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call. Conference Dial-In Numbers + 91 22 6280 1141 + 91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 Audio Link: Diamond Pass Log-In The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly- results To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: Univ ersal Access: Toll Free Number: 20
Page 21
For More Information For Investors: Pavleen Taneja Jubilant Ingrevia Limited. Ph: +91 120 436 1000 E-mail: pavleen.taneja@jubl.com Siddharth Rangnekar, CDR India Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com For Media: Sandipan Ghatak Ph: +91 120 436 1062 E-mail: sandipan.ghatak@jubl.com Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products. It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation. Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies. For more information, please visit: www.jubilantingrevia.com Thank you for your time Sahir Seth: Ph: +91 9999270119 E-mail: sahir.seth@adfactorspr.com The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. The picture can't be displayed. 21